2019
Adjuvant Hormonal Therapy for Low-Grade Endometrial Stromal Sarcoma
Deshmukh U, Black J, Perez-Irizarry J, Passarelli R, Levy K, Rostkowski A, Hui P, Rutherford TJ, Santin AD, Azodi M, Silasi DA, Ratner E, Litkouhi B, Schwartz PE. Adjuvant Hormonal Therapy for Low-Grade Endometrial Stromal Sarcoma. Reproductive Sciences 2019, 26: 600-608. PMID: 29843577, DOI: 10.1177/1933719118778801.Peer-Reviewed Original ResearchConceptsLow-grade endometrial stromal sarcomaRecurrence-free survivalStage I patientsEndometrial stromal sarcomaAromatase inhibitorsI patientsStage IIStromal sarcomaAdvanced low-grade endometrial stromal sarcomaMean recurrence-free survivalLonger recurrence-free survivalAdjuvant hormonal therapyMedian followProgestin groupUnderwent hysterectomyHormonal therapyDisease recurrenceSide effectsPatientsStage IProgestinsMonthsSarcomaDiseaseTreatment
2014
Hormonal Therapy for Aggressive Angiomyxoma
Schwartz PE, Hui P, McCarthy S. Hormonal Therapy for Aggressive Angiomyxoma. Journal Of Lower Genital Tract Disease 2014, 18: e55-e61. PMID: 24402356, DOI: 10.1097/lgt.0b013e3182a22019.Peer-Reviewed Original ResearchConceptsHormonal therapyMenopausal statusAggressive angiomyxomaPatient's menopausal statusRecurrent aggressive angiomyxomaEstrogen receptorRecurrent diseaseLeuprolide acetateProgestin receptor contentInitial surgical resectionExtent of diseaseTreatment of patientsMonthly leuprolideAdjuvant therapyNeoadjuvant therapyPelvic recurrencePostmenopausal womenPremenopausal womenSurgical resectionDefinitive treatmentHormonal agentsReceptor contentSensitive tumorsAromatase inhibitorsProgestin receptors